Trials / Unknown
UnknownNCT00673751
Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome
GLP-2 Mediated Increased SMA Blood Flow in Patients With Short Bowel Syndrome
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 8 (estimated)
- Sponsor
- Glostrup University Hospital, Copenhagen · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to investigate the effect of the enteric hormone Glucagon-like Peptide (GLP-2) on patients with short bowel syndrome
Detailed description
previous studies have shown that GLP-2 increases mesenteric blow flow, we wish to examine the effect of subcutaneus GLP-2 on patients with short bowl syndrome. The patients will single blinded been given 450 nmol GLP-2 and isotonic saline in order to act as their own reference.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GLP-2 | 450 nmol subcutaneous |
| DRUG | Placebo |
Timeline
- First posted
- 2008-05-07
- Last updated
- 2008-05-07
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT00673751. Inclusion in this directory is not an endorsement.